Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)

Citation
P. Carriere et al., Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group), EUR PSYCHIA, 15(5), 2000, pp. 321-329
Citations number
37
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Psychiatry,"Clinical Psycology & Psychiatry
Journal title
EUROPEAN PSYCHIATRY
ISSN journal
0924-9338 → ACNP
Volume
15
Issue
5
Year of publication
2000
Pages
321 - 329
Database
ISI
SICI code
0924-9338(200008)15:5<321:AHASBP>2.0.ZU;2-K
Abstract
In a multicentre, double-blind, flexible-dose study, 199 patients with para noid schizophrenia or schizophreniform disorders received haloperidol (10-3 0 mg/d) or amisulpride (400-1200 mg/d) for four months. More patients in th e haloperidol group withdrew prematurely (44% vs 26%; P = 0.0077) due to a higher incidence of adverse events. Amisulpride was at least as effective a s haloperidol in reducing the Brief Psychiatric Rating Scale (BPRS) total s core (-27.3 vs -21.9) (non-inferiority test; P < 0.001). The PANSS positive score improved to a similar extent in both groups whilst improvement in th e PANSS negative score was significantly greater with amisulpride (-10.5 vs -7.2; P = 0.01). The percentage of responders on the Clinical Global impre ssion scale was also significantly greater with amisulpride (71% vs 47%; P < 0.001). Both the Quality of Life Scale (QLS) and the Functional Status Qu estionnaire (FSQ) improved to a significantly greater extent under amisulpr ide. Haloperidol was associated with a greater incidence in extrapyramidal symptoms and with a greater increase in the Simpson-Angus score than was se en with amisulpride (0.32 vs 0.02; P < 0.001). In conclusion, amisulpride i s globally superior to haloperidol in the treatment of acute exacerbations of schizophrenia and significantly improves patients' quality of life and s ocial adjustment. (C) 2000 Editions scientifiques et medicales Elsevier SAS .